https://orcid.org/0000-0002-1692-6508
References
- Yao JC, Hassan M, Phan A, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26(18):3063–3072. doi:10.1200/JCO.2007.15.437718565894
- Cives M, Strosberg JR. Gastroenteropancreatic neuroendocrine tumors. CA Cancer J Clin. 2018. doi:10.3322/caac.21493
- Caplin ME, Pavel M, Cwikla JB, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371(3):224–233. doi:10.1056/NEJMoa131615825014687
- Rinke A, Muller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group. J Clin Oncol. 2009;27(28):4656–4663. doi:10.1200/JCO.2009.22.851019704057
- Novartis. Sandostatin® LAR Summary of Product Characteristics. Available from: https://www.ema.europa.eu/documents/referral/sandostatin-lar-article-30-referral-annex-iii_en.pdf 2018 Accessed 10, 2018.
- Ipsen Ltd. Somatuline® Autogel® Summary of Product Characteristics. Available from: https://www.medicines.org.uk/emc/product/8257/smpc 2018 Accessed 3, 2019.
- Johanson V, Wilson B, Abrahamsson A, et al. Randomized crossover study in patients with neuroendocrine tumors to assess patient preference for lanreotide Autogel® given by either self/partner or a health care professional. Patient Prefer Adherence. 2012;6:703–710. doi:10.2147/PPA.S3433723118529
- Adelman DT, Burgess A, Davies PR. Evaluation of long-acting somatostatin analog injection devices by nurses: a quantitative study. Med Devices (Auckl). 2012;5:103–109. doi:10.2147/MDER.S3783123293542
- Ware J, Kosinski M, Keller SD. SF-12: How to Score the SF-12 Physical and Mental Health Summary Scales. Boston, MA, USA: The Health Institute, New England Medical Center; 1998.
- Haugland T, Vatn MH, Veenstra M, Wahl AK, Natvig GK. Health related quality of life in patients with neuroendocrine tumors compared with the general Norwegian population. Qual Life Res. 2009;18(6):719–726. doi:10.1007/s11136-009-9487-x19479341
- Beaumont JL, Cella D, Phan AT, Choi S, Liu Z, Yao JC. Comparison of health-related quality of life in patients with neuroendocrine tumors with quality of life in the general US population. Pancreas. 2012;41(3):461–466. doi:10.1097/MPA.0b013e318232804522422138
- Gandek B, Ware JE, Aaronson NK, et al. Cross-validation of item selection and scoring for the SF-12 health survey in nine countries: results from the IQOLA Project. International Quality of Life Assessment. J Clin Epidemiol. 1998;51(11):1171–1178. doi:10.1016/s0895-4356(98)00109-79817135
- Singh S, Granberg D, Wolin E, et al. Patient-reported burden of a neuroendocrine tumor (NET) diagnosis: results from the first global survey of patients with NETs. J Glob Oncol. 2017;3(1):43–53. doi:10.1200/JGO.2015.00298028717741
- Lesén E, Granfeldt D, Houchard A. et al. Cost‐of‐illness of metastatic gastroenteropancreatic neuroendocrine tumours in Sweden—a population‐based register-linkage study. Eur J Cancer Care. 2019 e12983. doi:10.1111/ecc.12983